ArticleCureus2026
Reassessing Tuberculosis Treatment Outcomes by Sputum Liquid Culture Testing at the End of Treatment in Karnataka, India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a major global health condition, particularly in low- and middle-income countries. Treatment failure and relapse are of great concern, and treatment monitoring is largely dependent on smear microscopy. Smear microscopy has its limitations, particularly in identifying low bacillary loads and viable bacilli. This study aimed to estimate the prevalence of treatment failure and its associated risk factors among drug-sensitive TB (DSTB) patients using sputum liquid culture testing at the end of treatment.
methodsA cross-sectional study was conducted among microbiologically confirmed pulmonary DSTB patients between April and June 2024 in six randomly selected districts of Karnataka, India. Sputum samples obtained at the time of completion of treatment were cultured using the Mycobacterium Growth Indicator Tube (MGIT) liquid culture system in three culture and drug susceptibility testing (C-DST) laboratories in the state. Demographic and clinical information were accessed through Ni-kshay, the case-based web-based TB reporting system used in India. Statistical analysis was performed using Jamovi v2.3 (Jamovi Project, Sydney, Australia).
resultsAmong 511 patients enrolled, the mean age was 46 ± 17 years, 70.3% were male, 15.3% had a history of TB, 5.5% were HIV reactive, and 20.7% had diabetes. The mean BMI was 18.9 ± 2.8 kg/m². Liquid culture testing found 40 (7.8%; 95% CI: 5.6%-10.5%) patients to be culture positive. Thus, the TB treatment failure rate was 7.8%. Males and patients with a history of TB had relatively increased risks of treatment failure (RR: 1.27 and 1.18, respectively), but these were not statistically significant. Age, BMI, HIV reactivity, and diabetes also did not demonstrate significant associations with treatment failure.
conclusionThis study highlights the inadequacy of smear microscopy for treatment outcome measurement and shows that end-of-treatment liquid culture significantly enhances the detection of treatment failure. Scaling up the application of high-sensitivity tests, such as liquid culture, at the programmatic level could enhance outcome classification, enable timely clinical interventions, and reduce recurrence and transmission rates. Programmatic investment in sensitive diagnostic technology for diagnosis and treatment monitoring is essential in the strategy toward India's TB elimination goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.